GLP-1 Market
LLY $1364.73 ▼ -3.8% NVO $40.30 ▼ -4.5% PFE $29.88 ▼ -3.0% VKTX $25.79 ▼ -7.8% KLRA $12.17 ▼ -4.9% GPCR $19.08 ▼ -6.3% RHHBY $59.45 ▼ -2.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LM11A-31

LM11A-31

Company
Adam Boxer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for LM11A-31 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07173803

    The Progressive Supranuclear Palsy Clinical Trial Platform

    Not yet reported Adam Boxer 440 participants Est. completion 2030-09-28 21 sites Stand-alone
    Other conditions: Progressive Supranuclear Palsy(PSP)
    View official trial listing →
  • Completed NCT NCT03069014

    Study of LM11A-31-BHS in Mild-moderate AD Patients

    Not yet reported, Not yet reported PharmatrophiX Inc. 242 participants Est. completion 2020-06-08 21 sites
    Other conditions: Mild to Moderate Alzheimer's Disease
    View official trial listing →
  • Enrolling by invitation NCT NCT07264283

    The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

    Not yet reported Adam Boxer 147 participants Est. completion 2030-09-28 1 site Stand-alone
    Other conditions: PSP - Progressive Supranuclear Palsy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.